FAD Stock Overview
A clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Ayala Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.01 |
| 52 Week High | US$1.26 |
| 52 Week Low | US$0.001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 900.00% |
| 1 Year Change | -98.54% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| FAD | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.5% | 1.1% |
| 1Y | -98.5% | -13.0% | 16.0% |
Return vs Industry: FAD underperformed the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: FAD underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| FAD volatility | |
|---|---|
| FAD Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: FAD's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine FAD's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 21 | Ken Berlin | www.ayalapharma.com |
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company’s lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Ayala Pharmaceuticals, Inc. Fundamentals Summary
| FAD fundamental statistics | |
|---|---|
| Market cap | €1.26m |
| Earnings (TTM) | -€45.66m |
| Revenue (TTM) | €12.35k |
Is FAD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FAD income statement (TTM) | |
|---|---|
| Revenue | US$13.00k |
| Cost of Revenue | US$13.00k |
| Gross Profit | US$0 |
| Other Expenses | US$48.07m |
| Earnings | -US$48.07m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.98 |
| Gross Margin | 0% |
| Net Profit Margin | -369,784.62% |
| Debt/Equity Ratio | -33.3% |
How did FAD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/17 13:13 |
| End of Day Share Price | 2024/08/20 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ayala Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ahu Demir | Ladenburg Thalmann & Company |